1 |
Gan, F., Chen, X., Liao, S. F., Lv, C., Ren, F., Ye, G., Pan, C., Huang, D., Shi, J., Shi, X., Zhou, H., and Huang, K. (2014) Selenium-enriched probiotics improve antioxidant status, immune function, and selenoprotein gene expression of piglets raised under high ambient temperature. J. Agric. Food Chem. 62, 4502-4508.
DOI
|
2 |
George, W. L., Sutter, V. L., Citron, D., and Finegold, S. M. (1979) Selective and differential medium for isolation of Clostridium difficile. J. Clin. Microbiol. 9, 214-219.
|
3 |
Guslandi, M., Mezzi, G., Sorghi, M., and Testoni, P. A. (2000) Saccharomyces boulardii in maintenance treatment of Crohn's disease. Dig. Dis. Sci. 45, 1462-1464.
DOI
|
4 |
Hickson, M., D'Souza, A. L., Muthu, N., Rogers, T. R., Want, S., Rajkumar, C., and Bulpitt, C. J. (2007) Use of probiotic Lactobacillus preparation to prevent diarrhoea associated with antibiotics: Randomised double blind placebo controlled trial. BMJ 335, 80.
DOI
|
5 |
Johnston, B. C., Ma, S. S., Goldenberg, J. Z., Thorlund, K., Vandvik, P. O., Loeb, M., and Guyatt, G. H. (2012) Probiotics for the prevention of Clostridium difficile-associated diarrhea: A systematic review and meta-analysis. Ann. Intern. Med. 157, 878-888.
DOI
|
6 |
Kim, Y., Lee, J. W., Kang, S. G., Oh, S., and Griffiths, M. W. (2012) Bifidobacterium spp. influences the production of autoinducer-2 and biofilm formation by Escherichia coli O157:H7. Anaerobe. 18, 539-545.
DOI
|
7 |
Kondepudi, K. K., Ambalam, P., Nilsson, I., Wadstrom, T., and Ljungh, A. (2012) Prebiotic-non-digestible oligosaccharides preference of probiotic bifidobacteria and antimicrobial activity against Clostridium difficile. Anaerobe. 18, 489-497.
DOI
|
8 |
Liu, R., Suarez, J. M., Weisblum, B., Gellman, S. H., and Mc-Bride, S. M. (2014) Synthetic polymers active against Clostridium difficile vegetative cell growth and spore outgrowth. J. Am. Chem. Soc. 136, 14498-14504.
DOI
|
9 |
Louie, T. J., Miller, M. A., Mullane, K. M., Weiss, K., Lentnek, A., Golan, Y., Gorbach, S., Sears, P., and Shue, Y. K. (2011) Fidaxomicin versus vancomycin for Clostridium difficile infection. N. Engl. J. Med. 364, 422-431.
DOI
|
10 |
Yin, N., Li, J., He, Y., Herradura, P., Pearson, A., Mesleh, M. F., Mascio, C. T., Howland, K., Steenbergen, J., Thorne, G. M., Citron, D., Van Praagh, A. D. G., Mortin, L. I., Keith, D., Silverman, J., and Metcalf, C. (2015) Structure-activity relationship studies of a series of semisynthetic lipopeptides leading to the discovery of surotomycin, a novel cyclic lipopeptide being developed for the treatment of Clostridium difficileassociated diarrhea. J. Med. Chem. 58, 5137-5142.
DOI
|
11 |
Matsuguchi, T., Takagi, A., Matsuzaki, T., Nagaoka, M., Ishikawa, K., Yokokura, T., and Yoshikai, Y. (2003) Lipoteichoic acids from Lactobacillus strains elicit strong tumor necrosis factor alpha-inducing activities in macrophages through Toll-like receptor 2. Clin. Diagn. Lab. Immunol. 10, 259-266.
|
12 |
Rossland, E., Andersen Borge, G. I., Langsrud, T., and Sorhaug, T. (2003) Inhibition of Bacillus cereus by strains of Lactobacillus and Lactococcus in milk. Int. J. Food Microbiol. 89, 205-212.
DOI
|
13 |
McFarland, L. V. (2006) Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease. Am. J. Gastroenterol. 101, 812-822.
DOI
|
14 |
Mullane, K. M., Miller, M. A., Weiss, K., Lentnek, A., Golan, Y., Sears, P. S., Shue, Y. K., Louie, T. J., and Gorbach, S. L. (2011) Efficacy of fidaxomicin versus vancomycin as therapy for Clostridium difficile infection in individuals taking concomitant antibiotics for other concurrent infections. Clin. Infect. Dis. 53, 440-447.
DOI
|
15 |
Plummer, S., Weaver, M. A., Harris, J. C., Dee, P., and Hunter, J. (2010) Clostridium difficile pilot study: Effects of probiotic supplementation on the incidence of C. difficile diarrhoea. Int. Microbiol. 7, 59-62.
|
16 |
Ridwan, B. U., Koning, C. J., Besselink, M. G., Timmerman, H. M., Brouwer, E. C., Verhoef, J., Gooszen, H. G., and Akkermans, L. M. (2008) Antimicrobial activity of a multispecies probiotic (Ecologic 641) against pathogens isolated from infected pancreatic necrosis. Lett. Appl. Microbiol. 46, 61-67.
|
17 |
Teraguchi, S., Uhara, M., Ogasa, K., and Mitsuoka, T. (1978) Enumeration of bifidobacteria in dairy products. Jpn. J. Bacteriol. 33, 753-761.
DOI
|
18 |
Surawicz, C. M., Brandt, L. J., Binion, D. G., Ananthakrishnan, A. N., Curry, S. R., Gilligan, P. H., McFarland, L. V., Mellow, M., and Zuckerbraun, B. S. (2013) Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am. J. Gastroenterol. 108, 478-498.
DOI
|
19 |
Szajewska, H., Kotowska, M., Mrukowicz, J. Z., Arma, M., and Mikolajczyk, W. (2001) Efficacy of Lactobacillus GG in prevention of nosocomial diarrhea in infants. J. Pediatr. 138, 361-365.
DOI
|
20 |
Tejero-Sarinena, S., Barlow, J., Costabile, A., Gibson, G. R., and Rowland, I. (2012) In vitro evaluation of the antimicrobial activity of a range of probiotics against pathogens: Evidence for the effects of organic acids. Anaerobe. 18, 530-538.
DOI
|
21 |
Toure, R., Kheadr, E., Lacroix, C., Moroni, O., and Fliss, I. (2003) Production of antibacterial substances by bifidobacterial isolates from infant stool active against Listeria monocytogenes. J. Appl. Microbiol. 95, 1058-1069.
DOI
|
22 |
Wolvers, D., Antoine, J. M., Myllyluoma, E., Schrezenmeir, J., Szajewska, H., and Rijkers, G. T. (2010) Guidance for substantiating the evidence for beneficial effects of probiotics: Prevention and management of infections by probiotics. J. Nutr. 140, 698S-712S.
DOI
|
23 |
Biller, J. A., Katz, A. J., Flores, A. F., Buie, T. M., and Gorbach, S. L. (1995) Treatment of recurrent Clostridium difficile colitis with Lactobacillus GG. J. Pediatr. Gastroenterol. Nutr. 21, 224-226.
DOI
|
24 |
Yuan, J., Wang, B., Sun, Z., Bo, X., Yuan, X., He, X., Zhao, H., Du, X., Wang, F., Jiang, Z., Zhang, L., Jia, L., Wang, Y., Wei, K., Wang, J., Zhang, X., Sun, Y., Huang, L., and Zeng, M. (2008) Analysis of host-inducing proteome changes in Bifidobacterium longum NCC2705 grown in vivo. J. Proteome Res. 7, 375-385.
DOI
|
25 |
Yun, B., Oh, S., and Griffiths, M. W. (2014) Lactobacillus acidophilus modulates the virulence of Clostridium difficile. J. Dairy Sci. 97, 4745-4758.
DOI
|
26 |
Yun, B., Oh, S., Song, M., Hong, Y. S., Park, S., Park, D. J., Griffiths, M. W., and Oh, S. (2015) Inhibitory effect of epigallocatechin gallate on the virulence of Clostridium difficile PCR ribotype 027. J. Food Sci. 80, M2925-M2931.
DOI
|
27 |
Annuk, H., Shchepetova, J., Kullisaar, T., Songisepp, E., Zilmer, M., and Mikelsaar. M. (2003) Characterization of intestinal lactobacilli as putative probiotic candidates. J. Appl. Microbiol. 94, 403-412.
DOI
|
28 |
Asahara, T., Shimizu, K., Nomoto, K., Hamabata, T., Ozawa, A., and Takeda, Y. (2004) Probiotic bifidobacteria protect mice from lethal infection with shiga toxin-producing Escherichia coli O157:H7. Infect. Immun. 72, 2240-2247.
DOI
|
29 |
Badger, V. O., Ledeboer, N. A., Graham, M. B., and Edmiston, C. E. (2012) Clostridium difficile: Epidemiology, pathogenesis, management, and prevention of a recalcitrant healthcare-associated pathogen. J. Parenter. Enteral. Nutr. 36, 645-662.
DOI
|
30 |
Bezkorovainy, A. (1989) Nutrition and metabolism of bifidobacteria. In: Biochemistry and physiology of bifidobacteria. Miller-Catchpole, R. (eds) CRC press. Boca Raton, FL. pp. 93-129.
|
31 |
Buts, J. P., Corthier, G., and Delmee, M. (1993) Saccharomyces boulardii for Clostridium difficile-associated enteropathies in infants. J. Pediatr. Gastroenterol. Nutr. 16, 419-425.
DOI
|
32 |
Chen, X., Katchar, K., Goldsmith, J. D., Nanthakumar, N., Cheknis, A., Gerding, D. N., and Kelly, C. P. (2008) A mouse model of Clostridium difficile-associated disease. Gastroenterology 135, 1984-1992.
DOI
|
33 |
De Vuyst, L., Vrancken, G., Ravyts, F., Rimaux, T., and Weckx, S. (2009) Biodiversity, ecological determinants, and metabolic exploitation of sourdough microbiota. Food Microbiol. 26, 666-675.
DOI
|
34 |
Collado, M. C., Gonzalez, A., Gonzalez, R., Hernandez, M., Ferrus, M. A., and Sanz, Y. (2005) Antimicrobial peptides are among the antagonistic metabolites produced by Bifidobacterium against Helicobacter pylori. Int. J. Antimicrob. Agents 25, 385-391.
DOI
|
35 |
Cornely, O. A., Miller, M. A., Louie, T. J., Crook, D. W., and Gorbach, S. L. (2012) Treatment of first recurrence of Clostridium difficile infection: Fidaxomicin versus vancomycin. Clin. Infect. Dis. 55, S154-S161.
DOI
|